Cargando…
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
BACKGROUND: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro. Our study aimed to determine the frequency of mutatio...
Autores principales: | Elster, Naomi, Toomey, Sinead, Fan, Yue, Cremona, Mattia, Morgan, Clare, Weiner Gorzel, Karolina, Bhreathnach, Una, Milewska, Malgorzata, Murphy, Madeline, Madden, Stephen, Naidoo, Jarushka, Fay, Joanna, Kay, Elaine, Carr, Aoife, Kennedy, Sean, Furney, Simon, Mezynski, Janusz, Breathhnach, Oscar, Morris, Patrick, Grogan, Liam, Hill, Arnold, Kennedy, Susan, Crown, John, Gallagher, William, Hennessy, Bryan, Eustace, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047239/ https://www.ncbi.nlm.nih.gov/pubmed/30023006 http://dx.doi.org/10.1177/1758835918778297 |
Ejemplares similares
-
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
por: Coté, Damien, et al.
Publicado: (2018) -
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
por: Toomey, Sinead, et al.
Publicado: (2016) -
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
por: Milewska, Malgorzata, et al.
Publicado: (2018) -
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017) -
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
por: Toomey, Sinead, et al.
Publicado: (2017)